EVERSANA™ REIGNITE Commercialization serves as a catalyst for biopharma companies to address the management of their established brand portfolios. In a recent study, EVERSANA reviewed a comprehensive number of established brands and implemented the EVERSANA REIGNITE Commercialization model to slow financial loss and make a positive impact on revenue. With a combined investment, these established brands experienced a 1:3 to 3:6 return on investment ratios. This critical ROI observation illustrates how established brands have the opportunity to change the trajectory of these product portfolios and maximize value, utilizing resources already dedicated to the brand. Read the complete white paper on Reigniting Value in Established Brands.
It’s a long-standing perception that pharma overspends during launch, but we did not have the data or methodology to understand or validate this notion. Until now. New Research by the Numbers 10: Recent analysis across 10 traditional launches where the manufacturer opted to commercially launch a new drug $345M: The total cost for a manufacturer to commercially launch a new drug under traditional means is estimated at $345.6 million. $267M: An alternative outsourced commercial launch model averaged $267.4 million in investment. 23%: Overinvestment — confirmed Closer look: Results are consistent across company size and therapeutic expertise. The research team quantified the cost of a traditional launch by analyzing real-world examples. […]
Today’s economics simply do not support building commercial capabilities from scratch, only to dismantle that infrastructure until the next need arrives. Manufacturers will spend approximately $200 million of commercialization costs over three years leading up to the launch of their product, yet 66% of drugs do not meet launch expectations. In an era of specialty and rare-disease products, customized expertise and structures must be ready to adapt to varying market needs. And if the pandemic taught us anything, it is that successful organizations need to adapt to market demands and external forces out of their control. But while that’s true, and we know what needs to change, a survey of 30 biopharma commercialization […]
When MacroGenics partnered with EVERSANA, they had less than five months to launch their first product in the midst of the global pandemic. To meet their timeline and streamlined launch, MacroGenics needed a commercialization partner with an end-to-end platform that would allow them to build their capabilities expeditiously and strategically.
In thinking about the economics around the launch of pharmaceutical products, it is useful to compare the situation to another area that has seen its economics evolve in recent years: space travel. For decades, the only reusable space vehicle was NASA’s space shuttle. When the space shuttle was in operation, it could launch a payload of 27,500 kilograms for $1.5 billion, or $54,500 per kilogram. Between 1970 and 2000, the cost to launch a kilogram to space was reduced but then remained fairly stagnant, at an average of $18,500 per kilogram. Eventually, the space shuttle program was brought to an end, deemed too expensive, complex and unsafe. Now, Elon Musk’s […]